KOREA WHO
-
-
-
CEO & President of Samsung Bioepis
Christopher Hansung Ko
Bio Expert Emphasizing Fundamentals, Lays Foundation for Samsung's Bio Business
-
Last Updated on Mar 13, 2024
-
CEO & President of Samsung Bioepis
Life Summary
Ko Han-sung is the President and CEO of Samsung Bioepis.
As the inaugural CEO of Samsung Bioepis, he oversees the research and development of biosimilars (biopharmaceutical copy drugs).
Following Samsung Biologics' acquisition of all shares in Samsung Bioepis, he is exploring new ventures such as drug development.
He was born on April 20, 1963 (lunar calendar) in Busan and immigrated to the United States during his middle school years. He holds U.S. citizenship and his American name is 'Christopher Ko'.
He graduated from Prospect High School in California and from the Department of Biochemistry at UC Berkeley.
He earned his master's and doctoral degrees in genetic engineering from Northwestern University Graduate School.
He began his career at the bio venture company DiAx.
He has served as the head of the Biohealth Lab at Samsung Advanced Institute of Technology and as the Executive Vice President of Samsung Electronics' New Business Development Team.
He was appointed as the CEO when Samsung Bioepis was launched.
He is developing biosimilars to target the global market, including Europe and the United States.
Along with John Rim, the President and CEO of Samsung Biologics, he is a key figure responsible for Samsung Group's bio business.
#KoHanSung #SamsungBioepis #biotechnology #biosimilars #drugdevelopment #biopharmaceuticals #SamsungBiologics #biotechindustry #globalmarket #USimmigrant
As the inaugural CEO of Samsung Bioepis, he oversees the research and development of biosimilars (biopharmaceutical copy drugs).
Following Samsung Biologics' acquisition of all shares in Samsung Bioepis, he is exploring new ventures such as drug development.
He was born on April 20, 1963 (lunar calendar) in Busan and immigrated to the United States during his middle school years. He holds U.S. citizenship and his American name is 'Christopher Ko'.
He graduated from Prospect High School in California and from the Department of Biochemistry at UC Berkeley.
He earned his master's and doctoral degrees in genetic engineering from Northwestern University Graduate School.
He began his career at the bio venture company DiAx.
He has served as the head of the Biohealth Lab at Samsung Advanced Institute of Technology and as the Executive Vice President of Samsung Electronics' New Business Development Team.
He was appointed as the CEO when Samsung Bioepis was launched.
He is developing biosimilars to target the global market, including Europe and the United States.
Along with John Rim, the President and CEO of Samsung Biologics, he is a key figure responsible for Samsung Group's bio business.
#KoHanSung #SamsungBioepis #biotechnology #biosimilars #drugdevelopment #biopharmaceuticals #SamsungBiologics #biotechindustry #globalmarket #USimmigrant